Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, discusses challenges associated with the upscaling and outscaling of chimeric antigen receptor (CAR) T-cell therapies. Upscaling is especially an issue in developing therapies for allogeneic therapies and T-cell receptor (TCR) therapies due to increased material costs. Since complex gene editing techniques may logistically be difficult when scaling up, a shorter cultivation time may enable more efficient manufacturing. Decentralization and harmonizing regulatory guidelines are additional strategies that can enhance the production of cellular therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.